Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference30 articles.
1. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC 0941;Junttila;Cancer Cell,2009
2. Lapatinib plus capecitabine for HER2-positive advanced breast cancer;Geyer;N Engl J Med,2006
3. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer;Scaltriti;J Natl Cancer Inst,2007
4. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors;Burgess;Mol Cell,2003
5. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24
2. p95HER2 expression in HER2‐positive breast cancer with primary resistance;Precision Medical Sciences;2024-04-04
3. Anticancer therapeutic agents;Encyclopedia of Toxicology;2024
4. Research Progress on Prognostic Indicators of Neoadjuvant Therapy for HER-2 Positive Breast Cancer;Advances in Clinical Medicine;2024
5. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer;Molecular Immunology;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3